Atopic Dermatitis

Peter Lio, MD, discusses the value of hyperfocused meetings such as RAD and what sessions he is most looking forward to at RAD 2025.

Test your knowledge below on pooled data from the ARCADIA 1 and 2 trials and stay up to date with clinical advancements in atopic dermatitis.

This review highlights disparities among patients of color in terms of atopic dermatitis prevalence, management, and outcomes in the post-COVID-19 world.

Panelists discuss how shared decision-making in atopic dermatitis care involves collaboration between health care providers and patients, considering individual preferences, values, and treatment goals. This approach enhances treatment adherence and improves outcomes through personalized, informed choices.

Panelists discuss how standard first-line treatments for nonresponsive patients often include systemic therapies like corticosteroids or immunomodulators. Second-line options may involve biologics or advanced systemic agents. Patient input is crucial in tailoring treatments to preferences, needs, and risks.

These findings, while reassuring for JAK inhibitor prescription, nonetheless suggest that VTE-related recommendations for prescriptions should be maintained.

Test your knowledge below on pooled data from ADvocate1 and ADvocate2 trials and stay up to date with the latest clinical advancements in atopic dermatitis treatment.

Panelists discuss how the JADE EXTEND study (Shi 2022) found that most patients who achieved EASI-75 with dupilumab also responded to abrocitinib. Even some dupilumab nonresponders achieved EASI-75. Adverse events (AEs) included nausea, acne, and headache.

Panelists discuss how the JADE COMPARE study (Bieber 2021) found similar EASI-75 response rates at 16 weeks for abrocitinib (71.0% at 200 mg, 60.3% at 100 mg) and dupilumab (65.5%). Abrocitinib had more nausea/acne; dupilumab had more conjunctivitis. Adverse effect (AE) withdrawal rates were low.

These findings result from a systematic review and meta-analysis looking at the utilization of dupilumab among children and adolescents with atopic dermatitis.

These data point to the role of environmental factors in the development of atopic dermatitis and indicate targeted prevention strategies for those known to be impacted.

This quiz, the first in 4 part series, focuses on pivotal data from the INTEGUMENT trials in atopic dermatitis.

Panelists discuss how the Measure Up 1 and 2 studies (Simpson 2022) showed that at 52 weeks, 82.0% to 84.9% of upadacitinib patients achieved EASI-75. Common adverse effects (AEs) included acne, cough, and headache, with 4.5% to 7.2% withdrawal rates.

Panelists discuss how Janus kinase (JAK) inhibitors such as upadacitinib, abrocitinib, and baricitinib offer rapid, oral treatment for moderate to severe atopic dermatitis, differing from injectable biologics in administration, broader immunosuppression, and risk of adverse events like thromboembolism. They provide effective symptom control but require safety monitoring.

This interview with Ian Myles, MD, MPH, highlights his team’s recent findings on identifying dermatitis related to topical steroid withdrawal (TSW) versus atopic dermatitis.

These data highlight differences and similarities among dermatologists globally in their decisions related to the treatment of mild-to-moderate atopic dermatitis.

Panelists discuss how the 2-year ECZTEND study found tralokinumab effective for atopic dermatitis, with 82.5% achieving EASI-75 and 59.8%, EASI-90. Common adverse effects (AEs) included upper respiratory tract infections, dermatitis, headache, and conjunctivitis. The treatment-emergent adverse event (TEAE) withdrawal rate was 1.6%.

Panelists discuss how The LIBERTY AD OLE study (Beck 2024) showed sustained efficacy of treatment in atopic dermatitis, with 96.9% achieving EASI-50; 88.9%, EASI-75; and 80.7%, EASI-90 over 260 weeks. Common adverse events (AEs) included nasopharyngitis, atopic dermatitis (AD) worsening, upper respiratory tract infections, herpes infections, and conjunctivitis. Treatment-emergent adverse event (TEAE)–related withdrawal was 3.8%.

A recap of the 7 phase 3 trials presented during the 2025 AAD annual meeting's late-breaking sessions.

This interview highlights recent findings on roflumilast cream 0.05% for patients aged 2 to 5 years with mild to moderate atopic dermatitis.

New data presented at AAD 2025 point to impacts on multiple disease nodes as needed to achieve high levels of efficacy.

These data, presented at AAD 2025, highlight the efficacy of upadacitinib in clearing skin among patients with atopic dermatitis compared to those given dupilumab.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress.

A group of 9 experts reflect on what they are looking forward to most in 2025 following the AAD annual meeting.

This interview with Andrew Alexis, MD, MPH, features some of the most notable highlights from his AAD 2025 talks on therapeutic and diagnostic pearls for skin of color.